TLT Stock Overview
A clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Theralase Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.28 |
| 52 Week High | CA$0.38 |
| 52 Week Low | CA$0.14 |
| Beta | 1.35 |
| 11 Month Change | -25.00% |
| 3 Month Change | 50.00% |
| 1 Year Change | 58.33% |
| 33 Year Change | 26.67% |
| 5 Year Change | 14.00% |
| Change since IPO | -69.35% |
Recent News & Updates
Recent updates
Is Theralase Technologies (CVE:TLT) In A Good Position To Deliver On Growth Plans?
Jul 29
We're Not Very Worried About Theralase Technologies' (CVE:TLT) Cash Burn Rate
Apr 08Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation
Dec 24Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation
Sep 03Shareholder Returns
| TLT | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 0% | 4.5% | 0.7% |
| 1Y | 58.3% | 6.1% | 21.7% |
Return vs Industry: TLT exceeded the Canadian Medical Equipment industry which returned 3.7% over the past year.
Return vs Market: TLT exceeded the Canadian Market which returned 21.4% over the past year.
Price Volatility
| TLT volatility | |
|---|---|
| TLT Average Weekly Movement | 30.7% |
| Medical Equipment Industry Average Movement | 13.4% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: TLT's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: TLT's weekly volatility has increased from 19% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Roger Dumoulin-White | www.theralase.com |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ.
Theralase Technologies Inc. Fundamentals Summary
| TLT fundamental statistics | |
|---|---|
| Market cap | CA$68.13m |
| Earnings (TTM) | -CA$4.41m |
| Revenue (TTM) | CA$920.62k |
76.7x
P/S Ratio-16.0x
P/E RatioIs TLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLT income statement (TTM) | |
|---|---|
| Revenue | CA$920.62k |
| Cost of Revenue | CA$469.55k |
| Gross Profit | CA$451.07k |
| Other Expenses | CA$4.86m |
| Earnings | -CA$4.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 49.00% |
| Net Profit Margin | -478.72% |
| Debt/Equity Ratio | 0% |
How did TLT perform over the long term?
See historical performance and comparison